Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KRT005
MIFTS: 48

Keratoacanthoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Keratoacanthoma

About this section

MalaCards integrated aliases for Keratoacanthoma:

Name: Keratoacanthoma 12 77 56 45 15 74

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases Genetic diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3149
MeSH 45 D007636
NCIt 51 C3146
SNOMED-CT 69 58220003
UMLS 74 C0022572
Sources

Summaries for Keratoacanthoma

About this section
MalaCards based summary : Keratoacanthoma is related to basal cell carcinoma and verrucous carcinoma, and has symptoms including pruritus and exanthema. An important gene associated with Keratoacanthoma is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Lidocaine and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and colon, and related phenotypes are digestive/alimentary and integument

Wikipedia : 77 Keratoacanthoma (KA) is a common low-grade (unlikely to metastasize or invade) rapidly-growing skin... more...

Sources

Related Diseases for Keratoacanthoma

About this section

Diseases in the Keratoacanthoma family:

Familial Keratoacanthoma

Diseases related to Keratoacanthoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 basal cell carcinoma 30.6 KRT10 KRT17 TP53
2 verrucous carcinoma 30.4 KRT10 TP53
3 acanthoma 30.1 KRT10 KRT17
4 papilloma 30.1 CDKN1A KRT10 TP53
5 discoid lupus erythematosus 30.0 GZMB KRT10 KRT16
6 lichen planus 30.0 GZMB KRT10 KRT16 TP53
7 lynch syndrome i 29.7 MLH1 MSH2
8 keratosis, seborrheic 29.7 KRT10 KRT17 RBP1
9 bowen's disease 29.6 KRT10 KRT16 KRT17 MKI67
10 steatocystoma multiplex 29.4 KRT10 KRT16 KRT17
11 generalized eruptive keratoacanthoma 12.3
12 familial keratoacanthoma 12.3
13 muir-torre syndrome 12.1
14 vulvar keratoacanthoma-like carcinoma 12.1
15 multiple self-healing squamous epithelioma 11.9
16 palmoplantar carcinoma, multiple self-healing 11.3
17 squamous cell carcinoma 10.8
18 cheilitis 10.4 MSH2 TP53
19 brain ependymoma 10.4 MKI67 TP53
20 spitz nevus 10.4 MKI67 TP53
21 vulvar intraepithelial neoplasia 10.3 KRT10 TP53
22 oral leukoplakia 10.3 MKI67 TP53
23 lichen sclerosus 10.3 GZMB TP53
24 vulva squamous cell carcinoma 10.3 KRT17 TP53
25 adenosarcoma 10.3 MKI67 TP53
26 soft tissue sarcoma 10.3 MKI67 TP53
27 cervix uteri carcinoma in situ 10.3 KRT17 TP53
28 breast squamous cell carcinoma 10.3 KRT10 TP53
29 uterus carcinoma in situ 10.3 KRT17 TP53
30 basal cell carcinoma 1 10.3
31 melanoma 10.3
32 basal cell carcinoma, infundibulocystic 10.3 KRT10 KRT17
33 embryonal sarcoma 10.3 MKI67 TP53
34 large cell acanthoma 10.3 KRT10 KRT17
35 eccrine acrospiroma 10.3 KRT10 KRT17
36 basaloid squamous cell carcinoma 10.3 KRT17 TP53
37 cerebral primitive neuroectodermal tumor 10.3 MSH2 TP53
38 hidradenocarcinoma 10.2 MKI67 TP53
39 appendix carcinoid tumor 10.2 MLH1 MSH2
40 colorectal cancer, hereditary nonpolyposis, type 7 10.2 MLH1 MSH2
41 invasive bladder transitional cell carcinoma 10.2 CDKN1A TP53
42 adenosquamous colon carcinoma 10.2 MLH1 MSH2
43 bladder transitional cell papilloma 10.2 CDKN1A TP53
44 necrotizing sialometaplasia 10.2 GZMB MKI67 TP53
45 sebaceous adenoma 10.2 MLH1 MSH2
46 lower lip cancer 10.2 MLH1 MSH2
47 atypical follicular adenoma 10.2 CDKN1A TP53
48 anal fistula 10.2 MLH1 MSH2
49 lupus erythematosus 10.2
50 striate palmoplantar keratoderma 10.2 DSG1 KRT10

Graphical network of the top 20 diseases related to Keratoacanthoma:



Diseases related to Keratoacanthoma
Sources

Symptoms & Phenotypes for Keratoacanthoma

About this section

UMLS symptoms related to Keratoacanthoma:


pruritus, exanthema

MGI Mouse Phenotypes related to Keratoacanthoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 CDKN1A KRT16 KRT17 MLH1 MSH2 TP53
2 integument MP:0010771 9.17 CDKN1A DSG1 KRT16 KRT17 MLH1 MSH2
Sources

Drugs & Therapeutics for Keratoacanthoma

About this section

Drugs for Keratoacanthoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 5284616 6436030
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Azathioprine Approved Phase 4 446-86-6 2265
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
8 Peripheral Nervous System Agents Phase 4
9 Anesthetics Phase 4
10 Central Nervous System Depressants Phase 4
11 Anti-Arrhythmia Agents Phase 4
12 Anesthetics, Local Phase 4
13 Sodium Channel Blockers Phase 4
14 Diuretics, Potassium Sparing Phase 4
15 Cyclosporins Phase 4
16 Immunologic Factors Phase 4
17 Anti-Bacterial Agents Phase 4
18 Anti-Infective Agents Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Immunosuppressive Agents Phase 4
21 Calcineurin Inhibitors Phase 4
22 Antifungal Agents Phase 4
23
Dabrafenib Approved, Investigational Phase 3,Phase 2 1195765-45-7 44462760 44516822
24
Trametinib Approved Phase 3,Phase 2 871700-17-3 11707110
25 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
26
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
27
nivolumab Approved Phase 2 946414-94-4
28 Antineoplastic Agents, Immunological Phase 2
29
Sorafenib Approved, Investigational 284461-73-0 216239 406563
30
Methotrexate Approved 1959-05-2, 59-05-2 126941

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Pain Outcomes Following Intralesional Corticosteroid Injections Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
2 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
3 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Completed NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
4 Study of TVEC in Patients With Cutaneous Squamous Cell Cancer Recruiting NCT03714828 Phase 2 Injection of TVEC into target lesions - week 1-2;Injection of TVEC into target lesions 3wks after 1st injection;Injection of TVEC into target lesions 2wks after 2nd injection;Injection of TVEC into target lesions 2wks after 3rd injection
5 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
6 Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib Terminated NCT02314143 Phase 2 Dabrafenib;Trametinib
7 A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Withdrawn NCT02068079 Phase 1 Vemurafenib and Trientine
8 Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old Completed NCT03155217
9 Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Recruiting NCT02185560 Sorafenib (Nexavar, BAY43-9006)
10 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis Recruiting NCT01617018

Search NIH Clinical Center for Keratoacanthoma

Cochrane evidence based reviews: keratoacanthoma

Sources

Genetic Tests for Keratoacanthoma

About this section
Sources

Anatomical Context for Keratoacanthoma

About this section

MalaCards organs/tissues related to Keratoacanthoma:

42
Skin, Bone, Colon, Lung, Breast, Thyroid, Tongue
Sources

Publications for Keratoacanthoma

About this section

Articles related to Keratoacanthoma:

(show top 50) (show all 744)
# Title Authors Year
1
Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. ( 30353913 )
2019
2
Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin. ( 30790235 )
2019
3
Complete regression of keratoacanthoma with topical tazarotene gel 0.1%: therapeutic and pathophysiological perspectives. ( 28895378 )
2019
4
A prospective diagnostic study on povidone-iodine retention in lesions suspected to be squamous cell carcinoma or keratoacanthoma. ( 30109892 )
2019
5
Management of Keratoacanthoma: 157 Tumors Managed With Surgery or Intralesional Methotrexate. ( 30608293 )
2019
6
Angiolymphoid hyperplasia with eosinophilia with clinical pictures of keratoacanthoma: A rare case report. ( 30656039 )
2019
7
Koebnerization of Eruptive Keratoacanthoma Into Lesions of Classic Lichen Planus Treated With Oral Acitretin. ( 30789517 )
2019
8
Intralesional Methotrexate for the Treatment of Keratoacanthoma: The Neapolitan Experience. ( 30790234 )
2019
9
Intralesional therapy for the treatment of keratoacanthoma. ( 30866135 )
2019
10
Ineffectiveness of radiotherapy for the treatment of keratoacanthoma centrifugum marginatum: A case report. ( 30977219 )
2019
11
Malignant transformation of a conjunctival keratoacanthoma requiring enucleation. ( 30993300 )
2019
12
Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil. ( 31103317 )
2019
13
Spontaneous Regression of a Keratoacanthoma Centrifugum Marginatum. ( 31106023 )
2019
14
Eruptive Keratoacanthoma-Like Discoid Lupus Erythematosus. ( 28816744 )
2018
15
Generalized eruptive keratoacanthoma with vitiligo followed by the development of prurigo nodularis: A case report and published work review. ( 29058335 )
2018
16
Use of topical ephedrine and naphazoline in the treatment of a keratoacanthoma. ( 28712267 )
2018
17
Keratoacanthoma management: results of a survey of U.K. dermatologists and surgeons. ( 28758190 )
2018
18
Complete regression of crateriform verruca after partial biopsy: Another type of epithelial crateriform tumor or a subtype of keratoacanthoma? ( 29235666 )
2018
19
Successful Treatment of a Keratoacanthoma with Electrochemotherapy: A Case Report. ( 29368221 )
2018
20
Cutaneous intravascular CD30+ T-cell pseudolymphoma occurring in a regressing keratoacanthoma. ( 29369392 )
2018
21
Multiple keratoacanthoma and oral lichen planus successfully treated with systemic retinoids and review of multiple keratoacanthoma associated with lichen planus. ( 29577263 )
2018
22
KERATOACANTHOMA OF THE UPPER LIP: REVIEW OF THE LITERATURE AND REPORT OF CASE WITH CENTRAL UPPER LIP RECONSTRUCTION. ( 29578429 )
2018
23
Topical Imiquimod 5% as a Treatment Option in Solitary Facial Keratoacanthoma. ( 29610614 )
2018
24
Solitary Palmar Keratoacanthoma: Case Report. ( 29770284 )
2018
25
Topical aminolevulinic acid-photodynamic therapy in the treatment of keratoacanthoma: A case report. ( 29913213 )
2018
26
A Multiple Recurrent Keratoacanthoma of the Lower Leg After Repeated Wide-Excision and Mohs Micrographic Surgery. ( 29953419 )
2018
27
Embedded Tooth: Unique Mimicker of Keratoacanthoma. ( 30144411 )
2018
28
Keratoacanthoma-like cutaneous metastases in a case of squamous cell carcinoma of the tongue. ( 30381581 )
2018
29
Case of keratoacanthoma centrifugum marginatum treated with acitretin. ( 30389737 )
2018
30
Multiple disseminated keratoacanthoma-like nodules: a rare form of distant metastases to the skin. ( 30429717 )
2018
31
Keratoacanthoma Centrifugum Marginatum with Spontaneous Regression and Its Possible Differential Diagnosis. ( 30483096 )
2018
32
Efficacy and Safety of Intralesional Methotrexate in the Treatment of a Large Keratoacanthoma of the Dorsal Hand in a 99-Year-Old Woman. ( 30519171 )
2018
33
Calcified Keratoacanthoma with Tumoral Calcinosis in a 10-year-old Boy: A mere Co-incidence? ( 29263542 )
2017
34
Use of photodynamic therapy and acitretin in generalized eruptive keratoacanthoma of Grzybowski. ( 28948204 )
2017
35
Keratoacanthoma-Like Growths of Incontinentia Pigmenti Successfully Treated with Intralesional Methotrexate. ( 28414858 )
2017
36
Keratoacanthoma-like dermatofibroma: A dermoscopic challenge. ( 28087033 )
2017
37
Relationship between Human Papilloma Virus and Subungual Keratoacanthoma: Two Case Reports and the Outcomes of Surgical Treatment. ( 28232913 )
2017
38
Advances in histopathological diagnosis of keratoacanthoma. ( 28256761 )
2017
39
Keratoacanthoma Centrifugum Marginatum: Response to Acitretin. ( 28270315 )
2017
40
Keratoacanthoma en plaque/nodule: A brief report of the clinicopathological features of five cases. ( 28332728 )
2017
41
A Case of Exophytic Pilomatricoma Clinically Resembling Keratoacanthoma. ( 28392667 )
2017
42
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling. ( 28439948 )
2017
43
Cytokeratin 17 and Ki-67: Immunohistochemical markers for the differential diagnosis of keratoacanthoma and squamous cell carcinoma. ( 28454431 )
2017
44
Keratoacanthoma of the lip: A case report with emphasis on histogenesis. ( 28479697 )
2017
45
Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. ( 28501937 )
2017
46
Multiple keratoacanthoma centrifugum marginatum in a young boy, and review of the literature. ( 28543888 )
2017
47
Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use. ( 28584672 )
2017
48
Fine and Benign, Until It Becomes Malignant: The Enigmatic Keratoacanthoma. ( 28705282 )
2017
49
Keratoacanthoma centrifugum marginatum: an unusual clinical and histopathological diagnostic pitfall. ( 28730244 )
2017
50
Multiple keratoacanthoma centrifugum marginatum associated with juvenile idiopathic arthritis and persistent corneal epithelial defect: an unusual case. ( 28906090 )
2017
Sources

Variations for Keratoacanthoma

About this section
Sources

Expression for Keratoacanthoma

About this section
Search GEO for disease gene expression data for Keratoacanthoma.
Sources

Pathways for Keratoacanthoma

About this section

Pathways related to Keratoacanthoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 38
Show member pathways
 12.61 CDKN1A MLH1 MSH2 TP53
2
Pathways in cancer 38
12.55 CDKN1A MLH1 MSH2 TP53
3
Keratinization 67
Show member pathways
 12.19 DSG1 KRT10 KRT16 KRT17
4
Transcriptional misregulation in cancer 38
11.99 CDKN1A GZMB TP53
5
DNA Damage 4
11.82 CDKN1A MKI67 MLH1 MSH2 TP53
6
Colorectal Cancer Metastasis 65
11.78 CDKN1A MLH1 MSH2 TP53
7
Retinoblastoma (RB) in Cancer 1
11.6 CDKN1A RBP1 TP53
8
Direct p53 effectors 1
11.58 CDKN1A MLH1 MSH2 TP53
9
Glucocorticoid receptor regulatory network 1
11.55 CDKN1A KRT17 TP53
10
DNA damage_Role of Brca1 and Brca2 in DNA repair 23
11.31 MLH1 MSH2 TP53
11
Integrated Cancer Pathway 1
11.21 CDKN1A MSH2 TP53
12
Doxorubicin Pathway, Pharmacokinetics 62
Show member pathways
 11.1 MLH1 MSH2 TP53
13
GADD45 Pathway 65
11.08 CDKN1A TP53
14
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 62
11.02 MLH1 MSH2
15
TP53 Network 1
Show member pathways
 10.85 CDKN1A TP53
16
Platinum drug resistance 38
10.79 CDKN1A MLH1 MSH2 TP53
17
LncRNA-mediated mechanisms of therapeutic resistance 1
10.57 CDKN1A TP53
18
Transcriptional activation of p53 responsive genes 67
Show member pathways
 10.31 CDKN1A TP53
Sources

GO Terms for Keratoacanthoma

About this section

Cellular components related to Keratoacanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 condensed chromosome GO:0000793 9.16 MKI67 MLH1
2 intermediate filament GO:0005882 9.13 KRT10 KRT16 KRT17
3 mismatch repair complex GO:0032300 8.62 MLH1 MSH2

Biological processes related to Keratoacanthoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.84 CDKN1A MLH1 MSH2 TP53
2 cell cycle arrest GO:0007050 9.69 CDKN1A MSH2 TP53
3 cellular response to ionizing radiation GO:0071479 9.59 CDKN1A TP53
4 intrinsic apoptotic signaling pathway GO:0097193 9.58 CDKN1A TP53
5 mismatch repair GO:0006298 9.58 MLH1 MSH2
6 positive regulation of reactive oxygen species metabolic process GO:2000379 9.57 CDKN1A TP53
7 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.56 MSH2 TP53
8 keratinization GO:0031424 9.56 DSG1 KRT10 KRT16 KRT17
9 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.55 GZMB TP53
10 response to X-ray GO:0010165 9.52 CDKN1A MSH2
11 somatic hypermutation of immunoglobulin genes GO:0016446 9.49 MLH1 MSH2
12 isotype switching GO:0045190 9.48 MLH1 MSH2
13 determination of adult lifespan GO:0008340 9.46 MSH2 TP53
14 replicative senescence GO:0090399 9.43 CDKN1A TP53
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.4 MLH1 MSH2
16 positive regulation of isotype switching to IgA isotypes GO:0048298 9.37 MLH1 MSH2
17 signal transduction by p53 class mediator GO:0072331 9.32 CDKN1A TP53
18 somatic recombination of immunoglobulin gene segments GO:0016447 9.16 MLH1 MSH2
19 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.96 MLH1 MSH2
20 cornification GO:0070268 8.92 DSG1 KRT10 KRT16 KRT17

Molecular functions related to Keratoacanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatched DNA binding GO:0030983 8.96 MLH1 MSH2
2 guanine/thymine mispair binding GO:0032137 8.62 MLH1 MSH2
Sources

Sources for Keratoacanthoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....